The research group of Professor Johnny Ludvigsson at Linköping university have published a new paper in the scientific journal Diabetes/Metabolism Research and Reviews. In the paper they combine data from the previously published Phase II and Phase III clinical studies with the diabetes vaccine Diamyd
® in children and adolescents with type 1 diabetes.
The new paper concludes that treatment with two doses of GAD-alum in children and adolescents with recent-onset type 1 diabetes shows no adverse events and preserves residual insulin secretion.
Dr Ludvigsson is the Principal Investigator of the ongoing clinical study DIABGAD-1 with the diabetes vaccine Diamyd
®. The DIABGAD-1 study combines treatment with the diabetes vaccine Diamyd
® with relatively high doses of vitamin D and the anti-inflammatory drug ibuprofen. The purpose of the treatment is to preserve the body's own ability to control the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.
Read the article here